Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis
- PMID: 12481262
- DOI: 10.1002/elps.200290023
Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis
Abstract
Tumorigenesis is characterized by alterations of methylation profiles including loss and gain of 5-methylcytosine. Recently, we identified a single CpG, which seemed to be consistently hypomethylated in pilocytic astrocytomas but not in other gliomas. To evaluate its applicability as a biomarker, we examined its methylation status in a large panel of gliomas (n = 97). Methylation-dependent DNA sequence variation may be considered a kind of single nucleotide polymorphism (methylSNP). MethylSNPs can be easily converted into common SNPs of the C/T type by sodium bisulfite treatment of the DNA and afterwards subjected to conventional SNP typing. We adapted SnaPshot trade mark and Pyrosequencing trade mark to determine the methylation of our test CpG in a quantitative manner. The adapted methods, called SNaPmeth and PyroMeth, respectively, gave nearly identical results, however data obtained with PyroMeth showed less scattering. Furthermore, the integrated software for allele frequency determination from Pyrosequencing could be used directly for data analysis while SnaPmeth data had to be exported and processed manually. Although data did not confirm our previous result of a preferential hypomethylation of the tested CpG in pilocytic astrocytomas, we consider quantitative methylSNP analysis by SNaPmeth or PyroMeth a favorable alternative to existing high-throughput methylation assays. It combines single CpG analysis with accurate quantitation and is amenable to high throughput.
Similar articles
-
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.Clin Cancer Res. 2005 Feb 1;11(3):1119-28. Clin Cancer Res. 2005. PMID: 15709179
-
Epigenetic changes in pilocytic astrocytomas and medulloblastomas.Int J Mol Med. 2003 May;11(5):655-60. Int J Mol Med. 2003. PMID: 12684707
-
Single-nucleotide polymorphism analysis by pyrosequencing.Anal Biochem. 2000 Apr 10;280(1):103-10. doi: 10.1006/abio.2000.4493. Anal Biochem. 2000. PMID: 10805527
-
Restriction landmark genomic scanning: analysis of CpG islands in genomes by 2D gel electrophoresis.Methods Mol Biol. 2009;507:131-48. doi: 10.1007/978-1-59745-522-0_11. Methods Mol Biol. 2009. PMID: 18987812
-
[Towards a molecular classification of gliomas].Bull Cancer. 2005 Apr;92(4):310-6. Bull Cancer. 2005. PMID: 15888387 Review. French.
Cited by
-
Human Papillomavirus Type 16 L2 DNA Methylation in Exfoliated Cervical Cells From College-Age Women.J Low Genit Tract Dis. 2016 Oct;20(4):332-7. doi: 10.1097/LGT.0000000000000251. J Low Genit Tract Dis. 2016. PMID: 27518844 Free PMC article.
-
Matrix-assisted laser desorption/ionisation, time-of-flight mass spectrometry in genomics research.PLoS Genet. 2006 Jul;2(7):e100. doi: 10.1371/journal.pgen.0020100. PLoS Genet. 2006. PMID: 16895448 Free PMC article. Review.
-
Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells.J Mol Diagn. 2010 Mar;12(2):177-83. doi: 10.2353/jmoldx.2010.090106. Epub 2010 Jan 21. J Mol Diagn. 2010. PMID: 20093385 Free PMC article.
-
Determination of quantitative and site-specific DNA methylation of perforin by pyrosequencing.BMC Res Notes. 2009 Jun 12;2:104. doi: 10.1186/1756-0500-2-104. BMC Res Notes. 2009. PMID: 19523225 Free PMC article.
-
Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method.BMC Cancer. 2012 Jan 13;12:12. doi: 10.1186/1471-2407-12-12. BMC Cancer. 2012. PMID: 22243995 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical